Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: Role of myocyte structure and myocardial perfusion

Resuscitation

Volumn 82, Issue 8, 2011, Pages 1092-1099

  Vaillant, Fanny ^a   Dehina, Leila ^a   Mazzadi, Alejandro ^b   Descotes, Jacques ^c   Chevalier, Philippe ^d   Tabib, Alain ^a   Bui Xuan, Bernard ^a   Riera, Cécile ^a   Belhani, Dalila ^a   Timour, Quadiri ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c Centre de Pharmacovigilance   (France)

^d LOUIS PRADEL HOSPITAL   (France)

Author keywords

Cardiomyocyte morphology; Heart rate reduction; Ivabradine; Myocardial perfusion; Ventricular fibrillation

Indexed keywords

IVABRADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART ELECTROPHYSIOLOGY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEMODYNAMIC PARAMETERS; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SWINE;

ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART CONDUCTION SYSTEM; HEART RATE; MITOCHONDRIA, HEART; MUSCLE CELLS; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; SWINE; VENTRICULAR FIBRILLATION;

EID: 79960228386     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2011.03.032     Document Type: Article

References (37)

1. Roelandt J., Klootwijk P., Lubsen J., Janse M.J. Sudden death during longterm ambulatory monitoring. Eur Heart J 1984, 5:7-20.
2. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989, 69:1049-1169.
3. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989, 321:406-412.
4. Wyman M.G., Wyman R.M., Cannom D.S., Criley J.M. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol 2004, 94:545-551.
5. Timour Q., Aupetit J.F., Loufoua-Moundanga J., Gerentes-Chassagne I., Kioueh I., Faucon G. Class Ic antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ. Naunyn Schmiedebergs Arch Pharmacol 1991, 343:645-651.
6. Aupetit J.F., Timour Q., Larbre J.P., et al. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia - study in the porcine in situ heart. Cardiovasc Drugs Ther 1993, 7:217-223.
7. Aupetit J.F., Timour Q., Loufoua-Moundanga J., et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995, 25:810-816.
8. Bui-Xuan B., Aupetit J.F., Freysz M., Loufoua J., Faucon G., Timour Q. Cardiac beta-adrenoreceptor activation and ventricular fibrillation under normal and ischemic conditions. Cardiovasc Res 1996, 32:1056-1063.
9. Sulfi S., Timmis A.D. Ivabradine - the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract 2006, 60:222-228.
10. Borer J.S., Heuzey J.Y. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008, 15:461-473.
11. f selective channel inhibitor ivabradine in the treatment of chronic stable angina. Adv Ther 2009, 26:127-137.
12. Vaillant F., Timour Q., Descotes J., et al. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol 2008, 52:548-554.
13. + exchange inhibition on the in vitro damage induced by ischaemia reperfusion in the interventricular septum of the rabbit heart. Pharmacol Toxicol 2000, 86:222-227.
14. Venditti P., Bari A., Di Stefano L., Agnisola C., Di Meo S. Effect of T3 treatment on the response to ischemia-reperfusion of heart preparations from sedentary and trained rats. Pflugers Arch 2008, 455:667-676.
15. Heusch G., Skyschally A., Gres P., van Caster P., Schilawa D., Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008, 29:2265-2275.
16. Holzgrefe H.H., Everitt J.M., Wright E.M. Alpha-chloralose as a canine anesthetic. Lab Anim Sci 1987, 37:587-595.
17. Silverman J., Muir 3rd W.W. A review of laboratory animal anesthesia with chloral hydrate and chloralose. Lab Anim Sci 1993, 43:210-216.
18. Aupetit J.F., Loufoua-Moundanga J., Faucon G., Timour Q. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation. Br J Pharmacol 1997, 120:523-529.
19. Iida H., Rhodes C.G., de Silva R., et al. Myocardial tissue fraction - correction for partial volume effects and measure of tissue viability. J Nucl Med 1991, 32:2169-2175.
20. Gardiner S.M., Kemp P.A., March J.E., Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995, 115:579-586.
21. Monnet X., Ghaleh B., Colin P., de Curzon O.P., Giudicelli J.F., Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001, 299:1133-1139.
22. Monnet X., Colin P., Ghaleh B., Hittinger L., Giudicelli J.F., Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004, 25:579-586.
23. Ceconi C., Cargnoni A., Francolini G., Parinello G., Ferrari R. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res 2009, 84:72-82.
24. Zhang J., Liem D.A., Mueller M., et al. Altered proteome biology of cardiac mitochondria under stress conditions. J Proteome Res 2008, 7:2204-2214.
25. Liem D.A., Honda H.M., Zhang J., Woo D., Ping P. Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol 2007, 103:2129-2136.
26. Moshal K.S., Metreveli N., Frank I., Tyagi S.C. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 2008, 6:84-92.
27. Dong Z., Saikumar P., Weinberg J.M., Venkatachalam M.A. Calcium in cell injury and death. Annu Rev Pathol 2006, 1:405-434.
28. Gomez L., Chavanis N., Argaud L., et al. Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005, 289:H2153-H2158.
29. Heusch G., Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflugers Arch 1983, 397:284-289.
30. Indolfi C., Ross J. The role of heart rate in myocardial ischemia and infarction: implications of myocardial perfusion-contraction matching. Prog Cardiovasc Dis 1993, 36:61-74.
31. Henning R.J., Sawmiller D.R. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001, 49:27-37.
32. Indolfi C., Guth B.D., Miyazaki S., Miura T., Schulz R., Ross J. Heart rate reduction improves myocardial ischemia in swine: role of interventricular blood flow redistribution. Am J Physiol 1991, 261:H910-H917.
33. Buck J.D., Hardman H.F., Warltier D.C., Gross G.J. Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart. Circulation 1981, 64:708-715.
34. Matsuzaki M., Patritti J., Tajimi T., Miller M., Kemper W.S., Ross J. Effects of beta-blockade on regional myocardial flow and function during exercise. Am J Physiol 1984, 247:H52-60.
35. Simon L., Ghaleh B., Puybasset L., Giudicelli J.F., Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995, 275:659-666.
36. Heusch G., Baumgart D., Camici P., et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000, 101:689-694.
37. Tardif J.C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009, 30:540-548.